TiCARos teams up with Cartherics to lead development of CLIP-CAR technology

TiCARos and Cartherics Join Forces to Revolutionize NK Cell Therapy with CLIP-CAR Constructs

Cartherics and TiCARos have joined forces to develop a range of CLIP-CAR constructs that will be incorporated into Cartherics’ NK cells. The two companies will assess the function of these constructs both in vitro and in vivo.

TiCARos is known for developing novel chimeric antigen receptor (CAR)-T cell products for the treatment of solid and blood cancers, while Cartherics focuses on allogeneic NK cell therapy. Professor Alan Trounson, CEO of Cartherics, believes that integrating TiCARos’ CLIP-CAR technology with Cartherics’ platform could lead to more effective therapies. The companies have identified tissue factor (TF) and CD19 as their target tumor antigens for assessment of the CARs.

By combining their expertise in CAR-T and NK cell therapies, TiCARos and Cartherics aim to accelerate pipeline programs and expand opportunities beyond autologous cell therapies. The collaboration creates a pathway for advancing solid tumor pipeline programs and utilizing TiCARos’ technology in new ways. Depending on the results of their research collaboration, the two companies will explore development and commercialization opportunities together.

Leave a Reply

Servotech Power partners with Electra EV to develop advanced fast DC charging technology Previous post Electra EV and Servotech Power Systems Join Forces to Develop Fast DC Charging Technology for Indian Electric Vehicles
114-Year-Old Venezuelan Man Passes Away, Holds Title of World’s Oldest Person Next post The Extraordinary Life of Juan Vicente Perez Mora: The Guinness World Record Holder Who Passed Away at the Age of 114.